NEW DELHI, September 9, 2021 – SIRO Clinpharm Private Limited, India’s oldest clinical research organization has announced an agreement with JRF, a 45-year-old India based contract research organization, with an expansive portfolio of non-clinical regulatory research services to provide pre-clinical offerings. With this second strategic partnership, SIRO has now expanded its offering portfolio by providing end-to-end services. Last year in June 2020, the company had announced its first strategic partnership with Azidus to expand combined services offerings and avail access to an expanded client base for technical requisites of pharma and biotech industries.
SIRO focuses on patient studies and support trials from Phase II to Phase IV, whereas JRF offers GLP Compliant, Customer-focused, highly interactive services in the fields of Toxicology, Ecotoxicology, Chemistry, Environmental Fate, and Metabolism, and other regulatory testing requirements. JRF is well recognized for its expertise in Genetic Toxicology, repeat dose toxicology, (including the inhalation route), Reproductive toxicology, with strong bioanalytical support to assess not only systemic exposure but also product-specific immunotoxicity, biomarker assessment using HPLC-MS/MS, Flow Cytometry, and related state of the art equipment. This arrangement will help SIRO to expand their offerings with comprehensive services, to their expanded pool of clients.
Commenting on the agreement, Akshay Daftary, Director at SIRO Clinpharm said, “Strategic alliances are always mutually beneficial, fruitful and, in our case, both the alliances have been a strong testimony to it. The agreement with JRF resonates with the company’s firm belief and vision of providing end-to-end solutions. The agreement would definitely boost SIRO’s presence across geographies like Japan, EU, LatAm countries, Canada, and the USA.”
“The Preclinical testing is akin to an engine for the safety assessment. The needs of their sponsors stand provided with well-calibrated scientific solutions, in respect of potential obstacles during clinical testing. The interpretation of the Preclinical trials at JRF could offer indications to SIRO, to build up additional endpoints during the clinical trials. JRF’s reputed and well-received preclinical studies and interpretations will enable SIRO to stand benefitted in designing the trial protocols with a differentiation against the conventional service providers. With this agreement, both the companies stand to benefit, with their pooled mutual scientific talent and their capabilities to offer comprehensive solutions to their mutual sponsors”, said Dr. Sameer Navalgund, Director, JRF-Global.